GlassScriptPhysician profile
Joseph A Singer
NPI 1669435020
$3,238.32
in general payments reported to CMS, 2019-2025
21 companies · $703 in 2025
The $703 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $270 · 2021: $460 · 2022: $318 · 2023: $675 · 2024: $407 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.93 | 2019-2025 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $547.94 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $407.18 | 2021-2025 | Entyvio, Gattex |
| Braintree Laboratories, INC. | $347.48 | 2019-2024 | Suflave, Sutab |
| Abbott Laboratories | $301.87 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $145.98 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $142.64 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $136.34 | 2022-2023 | Ibsrela |
| Lilly USA, LLC | $93.49 | 2025 | Omvoh |
| Janssen Biotech, INC. | $77.12 | 2023-2025 | Stelara, Simponi, Remicade |
| Redhill Biopharma INC. | $70.80 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $63.45 | 2019-2020 | |
| Evoke Pharma, INC. | $43.64 | 2022 | |
| Celltrion USA INC. | $34.67 | 2025 | Vegzelma |
| Chiesi USA, INC. | $31.04 | 2022-2023 | Cleviprex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $27.54 | 2019 | |
| Qol Medical, LLC | $26.58 | 2021 | |
| W. L. Gore & Associates, INC. | $22.14 | 2021 | |
| Daiichi Sankyo INC. | $21.79 | 2020 | |
| Alfasigma USA, INC. | $16.22 | 2020 | |
| Masimo Corporation | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.